Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Glucomannan + inulin + psyllium** is an oral multi-fiber dietary supplement marketed as **Soloways** and manufactured by S.Lab. It combines the viscous soluble fibers glucomannan and psyllium with the fermentable prebiotic fiber inulin for weight-management use. The fibers increase gastrointestinal viscosity and water retention, can delay gastric emptying, promote fullness and satiety, reduce hunger, and undergo colonic fermentation. In a randomized, double-blind, placebo-controlled study in adults with overweight or obesity carrying specified FTO, LEP, LEPR, or MC4R polymorphisms, the combination was associated with greater 180-day reductions in body weight, body-mass index, fat mass, and visceral-fat rating than placebo, but gastrointestinal adverse effects were common.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucomannan + inulin + psyllium.